Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Amit Sanyal, MD: A Clinician’s Perspective

Jan

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Amit Sanyal, MD: A Clinician’s Perspective

Addition of Lapatinib to Chemoradiotherapy in Non–HPV-Related Head and Neck Cancer

HPV-Associated Oropharyngeal Cancer Intratreatment FDG-PET Response as a Biomarker for De-escalation of Radiotherapy

Addition of Cetuximab to Postoperative Radiotherapy in Intermediate-Risk Head and Neck Cancer

Addition of Bevacizumab to Pembrolizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

Chemoimmunotherapy Approach for Advanced HPV-Negative Head and Neck Cancer